Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells

Angiogenesis is the process by which new blood vessels are formed via proliferation of vascular endothelial cells. A variety of angiogenesis inhibitors that antagonize the effects of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have recently been identified. However, the mechanism by which these diverse angiogenesis inhibitors exert their common effects remains largely unknown. Caveolin-1 and -2 are known to be highly expressed in vascular endothelial cells both in vitro andin vivo. Here, we examine the potential role of caveolins in the angiogenic response. For this purpose, we used the well established human umbilical vein endothelial cell line, ECV 304. Treatment of ECV 304 cells with known angiogenic growth factors (VEGF, bFGF, or hepatocyte growth factor/scatter factor), resulted in a dramatic reduction in the expression of caveolin-1. This down-regulation event was selective for caveolin-1, as caveolin-2 levels remained constant under these conditions of growth factor stimulation. VEGF-induced down-regulation of caveolin-1 expression also resulted in the morphological loss of cell surface caveolae organelles as seen by transmission electron microscopy. A variety of well characterized angiogenesis inhibitors (including angiostatin, fumagillin, 2-methoxy estradiol, transforming growth factor-β, and thalidomide) effectively blocked VEGF-induced down-regulation of caveolin-1 as seen by immunoblotting and immunofluorescence microscopy. However, treatment with angiogenesis inhibitors alone did not significantly affect the expression of caveolin-1. PD98059, a specific inhibitor of mitogen-activated protein kinase and a known angiogenesis inhibitor, also blocked the observed VEGF-induced down-regulation of caveolin-1. Furthermore, we show that caveolin-1 can function as a negative regulator of VEGF-R (KDR) signal transduction in vivo. Thus, down-regulation of caveolin-1 may be an important step along the pathway toward endothelial cell proliferation.

[1]  R. D'Amato,et al.  Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. , 1997, Experimental eye research.

[2]  M. Lisanti,et al.  Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells , 1996, The Journal of Biological Chemistry.

[3]  W. Birchmeier,et al.  Inhibitory action of transforming growth factor beta on endothelial cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Saphir.  Angiogenesis: the unifying concept in cancer? , 1997, Journal of the National Cancer Institute.

[5]  R. Timpl,et al.  Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin , 1998, The EMBO journal.

[6]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[7]  H. Lodish,et al.  Caveolin Isoforms Differ in Their N-terminal Protein Sequence and Subcellular Distribution. IDENTIFICATION AND EPITOPE MAPPING OF AN ISOFORM-SPECIFIC MONOCLONAL ANTIBODY PROBE (*) , 1995, The Journal of Biological Chemistry.

[8]  P. Oh,et al.  Organized Endothelial Cell Surface Signal Transduction in Caveolae Distinct from Glycosylphosphatidylinositol-anchored Protein Microdomains* , 1997, The Journal of Biological Chemistry.

[9]  M. Lisanti,et al.  Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells , 1993, The Journal of cell biology.

[10]  R. F. Cook,et al.  Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease , 1994, The Journal of cell biology.

[11]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[12]  Richard G. W. Anderson,et al.  Localization of Platelet-derived Growth Factor-stimulated Phosphorylation Cascade to Caveolae (*) , 1996, The Journal of Biological Chemistry.

[13]  K. Preissner,et al.  Isolation and characterization of the circulating form of human endostatin , 1997, FEBS letters.

[14]  R. Tamargo,et al.  Angiogenesis inhibition by minocycline. , 1991, Cancer research.

[15]  R. Eddy,et al.  Identification of a new endothelial cell growth factor receptor tyrosine kinase. , 1991, Oncogene.

[16]  J. Folkman,et al.  Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Judah Folkman,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994 .

[18]  A. Mantovani,et al.  Molecular mechanisms of blood vessel formation. , 1997, Trends in biochemical sciences.

[19]  M. K. Jones,et al.  Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK. , 1998, Biochemical and biophysical research communications.

[20]  J. Waltenberger,et al.  The Vascular Endothelial Growth Factor Receptor KDR Activates Multiple Signal Transduction Pathways in Porcine Aortic Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[21]  J. Engelman,et al.  Caveolin‐mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo , 1998, FEBS letters.

[22]  H. Lodish,et al.  Molecular Cloning of Caveolin-3, a Novel Member of the Caveolin Gene Family Expressed Predominantly in Muscle (*) , 1996, The Journal of Biological Chemistry.

[23]  L. Helman,et al.  Suppression of rhabdomyosarcoma growth by fumagillin analog TNP‐470 , 1996, International journal of cancer.

[24]  Richard G. W. Anderson,et al.  Localization of Epidermal Growth Factor-stimulated Ras/Raf-1 Interaction to Caveolae Membrane (*) , 1996, The Journal of Biological Chemistry.

[25]  Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998 .

[26]  J. Alexander,et al.  Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins* , 1998, The Journal of Biological Chemistry.

[27]  J. Laterra,et al.  Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. , 1992, Biochemical and biophysical research communications.

[28]  Pingsheng Liu,et al.  Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Hogg,et al.  Generation of Angiostatin by Reduction and Proteolysis of Plasmin , 1997, The Journal of Biological Chemistry.

[30]  J. Engelman,et al.  Targeted downregulation of caveolin‐1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade , 1998, The EMBO journal.

[31]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Lisanti,et al.  Caveolins, a Family of Scaffolding Proteins for Organizing “Preassembled Signaling Complexes” at the Plasma Membrane* , 1998, The Journal of Biological Chemistry.

[33]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[34]  M. Yamaoka,et al.  Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). , 1993, Cancer research.

[35]  Michael S. Pepper,et al.  The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.

[36]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[37]  R. Bicknell.  Vascular targeting and the inhibition of angiogenesis. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  A. Baird,et al.  Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors. , 1986, Biochemical and biophysical research communications.

[39]  M. Stack,et al.  The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin , 1997 .

[40]  T. Yue,et al.  2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. , 1997, Molecular pharmacology.

[41]  M. Lisanti,et al.  Co-purification and Direct Interaction of Ras with Caveolin, an Integral Membrane Protein of Caveolae Microdomains , 1996, The Journal of Biological Chemistry.

[42]  M. Iruela-Arispe,et al.  Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Mineo,et al.  A detergent-free method for purifying caveolae membrane from tissue culture cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[45]  Richard J. Lee,et al.  Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo , 1998, The Journal of Biological Chemistry.

[46]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[47]  E. V. van Donselaar,et al.  Cell-type and Tissue-specific Expression of Caveolin-2 , 1997, The Journal of Biological Chemistry.

[48]  A. Harris,et al.  Mechanisms and therapeutic implications of angiogenesis. , 1996, Current opinion in oncology.